603880.SH
南卫股份
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 8.68
−0.23%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 584.7M | 600.5M | 602.6M | 600.1M | 545.4M |
| Cost of Revenue | 561.8M | 577.1M | 616.7M | 544.4M | 473.2M |
| Gross Profit | 22.9M | 23.4M | (14.1M) | 55.7M | 72.2M |
| Operating Expenses | |||||
| R&D Expense | 26.7M | 28.6M | 28.7M | 28.2M | 27.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 43.9M | 45.7M | 84.9M | 52.2M | 49.0M |
| Selling & Marketing Expense | 5.4M | 5.2M | 9.9M | 7.7M | 7.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 105.3M | 108.3M | 157.4M | 116.9M | 102.4M |
| Cost and Expenses | 667.1M | 685.4M | 774.1M | 661.3M | 575.6M |
| Operating Income (EBIT) | (89.8M) | (92.3M) | (197.7M) | (146.8M) | (29.4M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (90.6M) | (93.1M) | (200.9M) | (148.5M) | (29.3M) |
| Income Tax Expense | 7.6M | 8.0M | (10.4M) | (1.2M) | (14.4M) |
| Bottom Line | |||||
| Net Income | (98.9M) | (101.7M) | (190.7M) | (147.4M) | (14.6M) |
| Earnings from Cont. Ops | (98.2M) | (101.1M) | (190.5M) | (147.3M) | (14.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (98.9M) | (101.7M) | (190.7M) | (147.4M) | (14.6M) |
| Per Share | |||||
| Basic EPS | (CN¥0.34) | (CN¥0.35) | (CN¥0.66) | (CN¥0.51) | (CN¥0.05) |
| Diluted EPS | (CN¥0.34) | (CN¥0.35) | (CN¥0.66) | (CN¥0.51) | (CN¥0.05) |
| Revenue Per Share | CN¥2.07 | CN¥2.07 | CN¥2.09 | CN¥2.08 | CN¥1.86 |
| Shares | |||||
| Basic Shares Outstanding | 282.8M | 290.6M | 288.9M | 289.1M | 293.0M |
| Diluted Shares Outstanding | 282.8M | 290.6M | 288.9M | 289.1M | 293.0M |
| Profitability Metrics | |||||
| EBITDA | — | (45.8M) | (143.0M) | (90.2M) | 14.6M |
| D&A | — | 46.5M | 54.7M | 56.6M | 43.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026